Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Highlights Efforts To Bring Orphan Drugs To Market; Novo Nordisk, Alexion, Merck Serono Gain Approvals

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea FDA is promoting its work to bring orphan drugs to market in South Korea, and for the first time the agency released the names and makers of approved drugs in a press report to the media. Of the 23 biological drugs approved by KFDA during the first half of 2010, four were orphan drugs for the treatment of rare diseases
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC075460

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel